
==== Front
J Transl Med
J Transl Med
Journal of Translational Medicine
1479-5876
BioMed Central London

5637
10.1186/s12967-024-05637-2
Research
The gut microbiota modifies antibody durability and booster responses after SARS-CoV-2 vaccination
Seong Hye 123
Yoon Jin Gu 13
Nham Eliel 13
Choi Yu Jung 13
Noh Ji Yun 123
Cheong Hee Jin 123
Kim Woo Joo 123
Kim Eui Ho 4
Kim Chulwoo 35
Han Young-Hee 6
Lim Sooyeon limsooy@korea.ac.kr

23
http://orcid.org/0000-0002-0148-7194
Song Joon Young infection@korea.ac.kr

123
1 grid.222754.4 0000 0001 0840 2678 Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Gurodong-Ro 148, Guro-Gu, Seoul, 08308 Republic of Korea
2 grid.222754.4 0000 0001 0840 2678 Asia Pacific Influenza Institute, Guro Hospital, Korea University College of Medicine, Gurodong-Ro 148, Guro-Gu, Seoul, 08308 Republic of Korea
3 Vaccine Innovation Center-KU Medicine, Seoul, Republic of Korea
4 https://ror.org/04t0zhb48 grid.418549.5 0000 0004 0494 4850 Viral Immunology Laboratory, Institut Pasteur Korea, Seongnam, Republic of Korea
5 grid.222754.4 0000 0001 0840 2678 Department of Microbiology, Korea University College of Medicine, Seoul, Republic of Korea
6 https://ror.org/02wnxgj78 grid.254229.a 0000 0000 9611 0917 Department of Food and Nutrition, Chungbuk National University, Cheongju, Republic of Korea
6 9 2024
6 9 2024
2024
22 8273 5 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are pivotal in combating coronavirus disease 2019 (COVID-19); however, the declining antibody titers postvaccination pose challenges for sustained protection and herd immunity. Although gut microbiome is reported to affect the early antibody response after vaccination, its impact on the longevity of vaccine-induced antibodies remains unexplored.

Methods

A prospective cohort study was conducted involving 44 healthy adults who received two doses of either the BNT162b2 or ChAdOx1 vaccine, followed by a BNT162b2 booster at six months. The gut microbiome was serially analyzed using 16S rRNA and shotgun sequencing, while humoral immune response was assessed using a SARS-CoV-2 spike protein immunoassay.

Results

Faecalibacterium prausnitzii was associated with robust and persistent antibody responses post-BNT162b2 vaccination. In comparison, Escherichia coli was associated with a slower antibody decay following ChAdOx1 vaccination. The booster immune response was correlated with metabolic pathways involving cellular functions and aromatic amino acid synthesis.

Conclusions

The findings of this study underscored the potential interaction between the gut microbiome and the longevity/boosting effect of antibodies following vaccination against SARS-CoV-2. The identification of specific microbial associations suggests the prospect of microbiome-based strategies for enhancing vaccine efficacy.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12967-024-05637-2.

Keywords

Gut Microbiome
Vaccination
SARS-CoV-2
Half-life
Immunogenicity
http://dx.doi.org/10.13039/501100014188 Ministry of Science and ICT, South Korea NRF-2021M3E5D1A01015187 Seong Hye http://dx.doi.org/10.13039/501100002701 Ministry of Education NRF-2021R1I1A1A01050391 NRF-2018R1D1A1B07045711 Seong Hye Lim Sooyeon http://dx.doi.org/10.13039/501100003669 Korea Centers for Disease Control and Prevention 2021ER260300 Song Joon Young issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcintroduction

The global response to the coronavirus disease 2019 (COVID-19) pandemic has resulted in the development of new platform vaccines, including adenovirus vector, protein subunit, and mRNA vaccines, targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although variable by vaccine platforms, SARS-CoV-2 vaccines elicited a robust antibody response, reaching peak titers at approximately 3–4 weeks after the second dose [1–4]. However, the antibody titers gradually decline over time, reaching levels similar to those of the initial immune response after approximately 6 months [5].

Post-vaccination antibody longevity plays a critical role in sustaining individual protection and establishing herd immunity. Long-lived plasma cells originating from naïve or memory B-cells are important for maintaining antibody longevity, with memory B-cells further enabling the quick and efficient response of the immune system when re-exposed to the relevant viral strains [6–8]. Recent studies have suggested a relatively consistent presence of SARS-CoV-2 vaccine-induced memory B cells for a 3–6 month period after vaccination, but their levels may vary among individuals [9, 10].

Immune responses following vaccination vary among individuals owing to the influence of several factors [11, 12], including the gut microbiota. The microbiota plays a central role in the host immune system, particularly in the training and maturation of key components of the adaptive immune system [13, 14]. First, gut microbes stimulate and shape the adaptive immune system through exposure to their bacterial components and active metabolites [15]. Second, the gut microbiota directly influences and modulates adaptive immunity [16]. The sustained interaction and maintenance of the complex balance between the gut microbiota and adaptive immune system are essential for intestinal homeostasis and the inhibition of inflammation, ensuring an optimal immune response and long-term protection after vaccination [17].

The relationship between peak antibody titers and the gut microbiota after vaccination against SARS-CoV-2 has been investigated in several studies [18–20]. However, the relationship between the durability of vaccine-induced antibodies and microbiota has not yet been studied. In this study, we investigated the association between the gut microbiota and durability of humoral immunity, which may provide insights into approaches for enhancing vaccine efficacy.

Materials and methods

Study design and participants

In this study, we prospectively recruited healthy adults who had received a single dose of the BNT162b2 or ChAdOx1 vaccines and were scheduled to get the second dose of the primary vaccination series. After enrollment, the participants were divided into two cohorts: those receiving two doses of the BNT162b2 vaccine (BNT162b2 cohort) and those receiving two doses of the ChAdOx1 vaccine (ChAdOx1 cohort). Following this, all participants were administered a booster vaccination with the BNT162b2 vaccine. Fecal and blood samples were collected at four time points: V1 (prior to the second dose of the primary vaccination series), V2 (3 weeks after the second dose), V3 (6 months after the second dose and prior to the booster dose), and V4 (3 weeks after the BNT162b2 booster dose). Data on patient demographics, medications, probiotics, supplements, laboratory results, and dietary records were collected at each time point.

Participants were excluded if they received medications that could have affected the gut microbiota, including antibiotics, laxatives, and motility drugs in the month prior to vaccination; had a history of positive SARS-CoV-2 results by nasopharyngeal PCR testing; or tested positive for serum antinuclear capsid protein (N) IgG. None of the participants contracted COVID-19 during the study period, as confirmed by anti-N IgG antibody testing (Abbott Laboratories, Chicago, IL, USA).

Fecal samples were collected in a nucleic acid preservation medium using Fecal Swab DNA Preservation and Transport Kits (Noble Bio, Hwaseong, South Korea) and stored at − 80 °C. Blood samples were collected in serum separation tubes via venipuncture. After centrifugation at 2500 rpm and − 4 °C for 10 min, the serum was transferred to clean plastic screw-capped vials and stored at − 80 °C.

The study protocol was approved by the Institutional Review Board of Korea University Guro Hospital (2021GR0097). Informed consent was obtained from all participants. All procedures were performed in accordance with the ethical standards of the relevant institutional and/or national research committees, the Helsinki Declaration of 1964 and its subsequent amendments, or comparable ethical standards.

Classification of study groups based on the immune response after vaccination

Humoral immune responses were assessed using corresponding serum samples. Anti-S titers were measured using the Elecsys® Anti-SARS-CoV-2 S assay kit (Roche, Rotkreuz, Switzerland) according to the manufacturer's protocol. Titers below the lower limit of quantitation were set to 0.4 U/mL.

The half-life of anti-S antibodies was determined from the V2–V3 time points. To investigate the microbial factors associated with the durability of vaccine-induced antibodies, participants from the BNT162b2 and ChAdOx1 vaccine cohorts were divided into slow- and fast-decay groups based on the median values of antibody half-life.

After receiving the BNT162b2 booster, the acute antibody responses were evaluated by comparing the fold changes in antibody titers between V3 and V4. Using the median fold-change in antibody titers across all booster vaccine recipients, participants were classified as either high or low responders.

Analysis pipeline for 16S rRNA

Total DNA was extracted using the FastDNA® SPIN Kit for Soil (MP Biomedicals, Santa Ana, CA, USA) according to the manufacturer's instructions. The extracted DNA was PCR amplified by CJ Bioscience (Seoul, Republic of Korea) using fusion primers targeting the V3–V4 regions of the 16S rRNA gene. PCR products were confirmed by electrophoresis on a 1% agarose gel, followed by visualization using the Gel Doc system (Bio-Rad, Hercules, CA, USA). The amplified products were purified using a CleanPCR kit (CleanNA, Waddinxveen, The Netherlands). Equal concentrations of purified products were pooled, and short fragments (nontarget products) were removed using a CleanPCR kit (CleanNA). The quality and size of products were assessed on a Bioanalyzer 2100 system (Agilent, Palo Alto, CA, USA) using a DNA 7500 chip. Mixed amplicons were pooled and sequenced using an Illumina MiSeq Sequencing System (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. Analysis was performed using the EzBioCloud 16S-based Microbiome Taxonomic Profiling (MTP) and CJ Bioscience's bioinformatics cloud platform (https://www.ezbiocloud.net). All microbiome count data were normalized to that of 1000 read counts before further use.

The alpha diversity indices (abundance-based coverage estimator [ACE] and Simpson) were calculated as previously described [21–26]. To visualize sample differences, beta diversity distances were calculated using the Jensen–Shannon, Bray–Curtis, Generalized UniFrac, and Fast UniFrac algorithms as appropriate [27–30]. With respect to antibody durability and fold-change, taxonomic and functional biomarkers were identified using the linear discriminant analysis (LDA) effect size method [31]. An LDA effect size of ≥ 2.0 was considered significant. Functional profiles were predicted using PICRUSt and MinPath algorithms [32, 33]. Raw reads were quality-checked, and low-quality (< Q25) reads were filtered using Trimmomatic ver. 0.32. After quality control processing, paired-end sequence data were merged using the fastq_mergepairs command in VSEARCH ver. 2.13.4. with the default parameters. Next, the primers were trimmed using the Myers–Miller alignment algorithm at a similarity cut-off of 0.8 [34]. Nonspecific amplicons, such as those not encoding 16S rRNA, were detected using the nhmmer algorithm in the HMMER software package ver. 3.2.1 with hmm profiles [35]. Unique reads were extracted, and redundant reads were clustered with unique reads using the deep-full-length command in VSEARCH [36]. Taxonomic assignment was performed using the EzBioCloud 16S rRNA database with the usearch_global command in VSEARCH, followed by a more precise pairwise alignment [34, 36, 37]. Chimeric reads were filtered to obtain reads with < 97% similarity through reference-based chimeric read detection using the UCHIME algorithm and nonchimeric 16S rRNA database from EzBioCloud [38]. After chimeric filtering, reads not identified to the species level (< 97% similarity) in the EzBioCloud database were compiled, and the cluster_fast command was used for de novo clustering to generate additional OTUs. OTUs with single reads (singletons) were excluded from further analysis [36]. Secondary analyses, including diversity calculations and biomarker discovery, were performed using in-house programs from CJ Bioscience.

Analysis pipeline for shotgun sequencing

Genomic DNA was extracted from isolates using the FastDNA™ Spin Kit for Soil (MP Biomedicals) according to the manufacturer’s instructions. The concentration of the extracted DNA was quantified using a Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA). Sequencing libraries were constructed using the NEBNext Ultra II FS DNA Library Prep Kit for Illumina (NEB, Ipswich, MA, USA) according to the manufacturer’s protocol for use with inputs ≤ 100 ng. Metagenome sequencing was performed on the NextSeq 1000 system with 2 × 150 bp paired-end reads using a 300-cycle (NextSeq 1000 Reagent Kit) sequencing kit. The profiling process began by surveying the potential presence of bacterial and archaeal species in each raw metagenomic sample read using Kraken2 [39] and a prebuilt core gene database [40] containing k-mers (k = 35) of reference genomes obtained from the EzBioCloud database [37]. After acquiring a list of candidate species, a custom bowtie2 [41] database was built using the core genes of species identified during the first step. The raw samples were then mapped against the bowtie2 database using the very-sensitive option and a phred33 quality threshold. Samtools [42] was used to convert and sort the output BAM file. The coverage of the mapped reads against the BAM file was obtained using Bedtools [43]. To avoid false positives, an in-house script was used to quantify all reads mapped to a given species only if the total coverage of their core genes was ≥ 25%. Finally, species abundance was calculated using the total number of count reads, while normalized species abundance was calculated using the total length of all core genes.

Taxonomic data were calculated as the species ratio based on the analysis using the Bacteria and Archaea database. In contrast, functional data were obtained as counts per million values based on the analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Enzyme commission, and EggNOG databases [44]. Functional profiling was conducted using HUMAnN (the HMP Unified Metabolic Analysis Network). HUMAnN uses metagenomic data as input and processes them to estimate the functions of the microbial community. This was done by comparing the genetic sequences to a database of known microbial genes and pathways and then inferring the functions of the community [45].

Statistical analysis

All continuous variables are expressed as the median ± interquartile range (IQR; third IQR–first IQR), whereas categorical variables are presented as numbers (percentages). Nonparametric tests were used to compare the differences between different groups. Statistical analysis was performed using the LDA effect size method to support high-dimensional class comparisons with a particular focus on metagenomic analyses and depicted using the R Statistical Software (version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria) with the ggplot2 and vegan packages.

Results

From March to April 2021, we prospectively recruited 44 healthy adults who received the first dose of either the BNT162b2 (n = 23) or ChAdOx1 (n = 21) vaccine and were scheduled to receive the second dose of the primary vaccination series (Fig. 1). The median age of the study participants was 31 ± 8.5 years, with 75% (33) being women. The baseline geometric mean titer of anti-S IgG of all participants was 98.3 U/mL (Table S1). We analyzed fecal and blood samples at four time points: V1 (prior to the second dose), V2 (3 weeks after the second dose), V3 (6 months after the second dose and prior to the booster dose), and V4 (3 weeks after the BNT162b2 booster dose). After the two-dose primary vaccination series, the median antibody half-life between V2 and V3 was 141.0 d in the BNT162b2 cohort, whereas it was 63.4 d in the ChAdOx1 cohort. Based on the half-life of anti-S IgG antibodies, each vaccination cohort was classified into slow- and fast-decay groups (Tables S2 and S3). After the booster dose vaccination, the BNT162b2 recipients were divided into two groups (high versus low responders) based on the median value (34-fold) of the antibody fold-change from V3 to V4 (Table S4).Fig. 1 Schematic study diagram

Of the 176 stool samples collected, 13 were excluded because of poor quality, leaving 36 (V1), 39 (V2), and 44 (V3 and V4) samples for gut microbiota analysis. Using corresponding blood samples, we evaluated the anti-S humoral immune response. During the follow-up period, the study participants did not show any major changes in their dietary habits (data not shown; a pseudonymized individual study dataset can be made available upon request).

Association between anti-S antibody half-life and gut microbiota using 16S rRNA sequencing in the BNT162b2 cohort

Regarding alpha diversity, we calculated species richness and diversity using the abundance-based coverage estimator (ACE) and Simpson indices, which revealed significant differences between the slow- and fast-decay groups (Fig. 2A). The ACE index in the slow-decay group at V2 was significantly higher than that in the fast-decay group at V2 (p = 0.035) and V3 (p = 0.012), indicating higher species richness in the former. Similarly, the Simpson index in the slow-decay group at V2 was significantly lower (higher diversity) than that in the fast-decay group at both V2 (p = 0.035) and V3 (p = 0.049). Interestingly, these differences in the alpha diversity indices between the two groups disappeared six months after the second dose (V3) (ACE index, p = 0.176; Simpson index, p = 0.712). Analysis using the Jensen–Shannon algorithm, excluding unclassified operational taxonomic units (OTUs) (Fig. 2B), revealed apparent differences in beta diversity values between V2 and V3 in the slow-decay (p = 0.018) and fast-decay (p = 0.002) groups.Fig. 2 Alpha and beta diversity comparison of the anti-S antibody titer between the slow- and fast-decay groups (BNT162b2 cohort). A Alpha diversity (ACE and Simpson). B Principal coordinate analysis (PCoA) using the Jensen–Shannon algorithm, excluding unclassified operational taxonomic units (OTUs)

Following the two-dose primary vaccination series, the slow-decay group exhibited distinctly abundant bacterial species in the gut microbiota from stool samples collected 3 weeks after the second dose compared with those in the fast-decay group (Table 1 and Table S5). Certain bacterial species were significantly associated with slower antibody decay in individuals who received the BNT162b2 vaccine. Faecalibacterium prausnitzii was the most abundant species, with a linear discriminant analysis (LDA) effect size of 4.26175 (p = 0.04095). Prevotella_uc and PAC001304_s, both from the genus Prevotella, showed LDA effect sizes of 4.25488 (p = 0.00819) and 4.15907 (p = 0.04801), respectively. Another notable species, Gemmiger formicilis from the family Ruminococcaceae, had an LDA effect size of 3.91776 (p = 0.03896), whereas Bacteroides dorei, a member of the family Bacteroidaceae, had an LDA effect size of 3.71884 (p = 0.01251). Similarly, Agathobacter rectalis, a member of the family Lachnospiraceae, had an LDA effect size of 3.49743 (p = 0.04703). In addition, PAC001173_s, PAC000195_s, JPJG_s, PAC001037_s, PAC001187_s, PAC001335_s, and Bacteroides_uc showed pronounced LDA effect sizes, indicating their potential contributions to the modulation of vaccine-induced immunity. At the genus level (Table S5), Prevotella had an LDA effect size of 4.62838 (p = 0.0147), followed by Faecalibacterium with an effect size of 4.26036 (p = 0.04791). Other significant genera were Subdoligranulum (LDA = 3.98239, p = 0.01467), Agathobacter (LDA = 3.50072, p = 0.04703), and Eubacterium_g23 (LDA = 3.05084, p = 0.00962). Finally, the compelling LDA effect sizes of PAC000195_g, PAC000196_g, PAC000692_g, and PAC001236_g suggested their potential effect in vaccine-mediated host immune responses.Table 1 Species-level taxonomic markers linked to extended antibody durability following the two-dose primary vaccination series

Taxon name	Taxon rank	Taxonomy	LDA effect size	p-value	
BNT162b2	
 Faecalibacterium prausnitzii	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Faecalibacterium	4.26175	0.04095	
 Prevotella_uc	Species	Bacteria: Bacteroidetes: Bacteroidia: Bacteroidales: Prevotellaceae: Prevotella	4.25488	0.00819	
 PAC001304_s	Species	Bacteria: Bacteroidetes: Bacteroidia: Bacteroidales: Prevotellaceae: Prevotella	4.15907	0.04801	
 Gemmiger formicilis	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Subdoligranulum	3.91776	0.03896	
 Bacteroides dorei	Species	Bacteria: Bacteroidetes: Bacteroidia: Bacteroidales: Bacteroidaceae: Bacteroides	3.71884	0.01251	
 Agathobacter rectalis	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: Agathobacter	3.49743	0.04703	
 PAC001173_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Subdoligranulum	3.14941	0.04366	
 PAC000195_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: PAC000195_g	3.1406	0.0476	
 JPJG_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Oscillibacter	3.01913	0.04765	
 PAC001037_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Oscillibacter	2.6809	0.01235	
 PAC001187_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Oscillibacter	2.6189	0.00492	
 PAC001335_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: PAC000196_g	2.55763	0.03297	
 Bacteroides_uc	Species	Bacteria: Bacteroidetes: Bacteroidia: Bacteroidales: Bacteroidaceae: Bacteroides	2.53203	0.03742	
 Bacteroides xylanisolvens	Species	Bacteria: Bacteroidetes: Bacteroidia: Bacteroidales: Bacteroidaceae: Bacteroides	2.38654	0.04201	
 PAC001229_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: PAC000692_g	2.32714	0.02256	
 PAC001162_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Sporobacter	2.23478	0.04096	
 PAC001306_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Sporobacter	2.21794	0.04844	
 PAC001467_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: PAC000692_g	2.13406	0.01007	
 PAC001130_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Oscillibacter	2.12692	0.03535	
 PAC001236_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Mogibacterium_f: PAC001236_g	2.11986	0.01768	
 PAC001449_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: PAC001043_g	2.08894	0.01923	
ChAdOx1	
 Escherichia coli	Species	Bacteria: Proteobacteria: Gammaproteobacteria: Enterobacterales: Enterobacteriaceae: Escherichia	3.85796	0.00937	
LDA, linear discriminant analysis. LDA effect size and p-value are expressed as values of V2

Following the BNT162b2 administration, we performed 16S rRNA gene sequencing analysis of the gut microbiota and identified specific functional marker proteins that may affect antibody decay rates (Table S6). Interestingly, we found that the key functional markers were starch-binding outer membrane proteins from the SusD/RagB family (LDA = 3.02715, p = 0.02956), RNA polymerase sigma-70 factor from the ECF subfamily (LDA = 2.89815, p = 0.03486), and iron complex outer membrane receptor protein (LDA = 2.89246, p = 0.01222). Other noteworthy markers included the TonB-dependent starch-binding outer membrane protein SusC (LDA = 2.83329, p = 0.03486), an uncharacterized protein (LDA = 2.58362, p = 0.00686), a multidrug resistance protein of the MATE family (LDA = 2.56360, p = 0.04095), a HlyD family secretion protein (LDA = 2.53494, p = 0.01470), and integrase/recombinase XerD (LDA = 2.51074, p = 0.04791).

Further investigation into the functional capabilities of the microbiota revealed specific modules and pathways that may influence vaccine immunogenicity. PICRUSt analysis revealed that F-type ATPase (LDA = 2.93490, p = 0.00686) and an incomplete reductive citrate cycle (LDA = 2.69979, p = 0.04095) were significantly associated with a longer antibody half-life. MinPath analysis highlighted the positive relationship between a longer half-life and lysine biosynthesis via the aromatic amino acid pathway (LDA = 2.74262, p = 0.01470) and formaldehyde assimilation via the serine pathway (LDA = 2.73185, p = 0.01761). Furthermore, PICRUSt analysis identified the lysosome (LDA = 2.53934, p = 0.02956) and photosynthesis (LDA = 2.46671, p = 0.00835) pathways, whereas MinPath analysis revealed the vitamin B6 metabolism (LDA = 3.15938, p = 0.01382) and lipopolysaccharide biosynthesis (LDA = 3.09433, p = 0.01162) pathways to be more abundant in the slow-decay group.

Association between anti-S antibody half-life and gut microbiota using 16S rRNA sequencing in the ChAdOx1 cohort

Unlike the BNT162b2 cohort, we did not detect any significant differences in alpha and beta diversity between groups in the ChAdOx1 cohort (data not shown). Postvaccination analysis of stool samples collected from ChAdOx1 recipients 3 weeks after the second dose revealed the presence of distinct gut bacterial species associated with longer antibody half-lives (Table 1 and Table S5). Specifically, Escherichia coli was associated with slow antibody decay (LDA effect size of 3.85796, p = 0.00937). At the genus level, Alistipes was significantly more abundant, with an LDA of 4.46179 (p = 0.03844), followed by Escherichia (LDA = 3.8579, p = 0.00937), Parabacteroides (LDA = 3.85644, p = 0.01235), and Enterococcus (LDA = 3.23579, p = 0.04323).

Detailed 16S rRNA gene analysis of samples from ChAdOx1 recipients revealed specific functional markers based on their gut microbiota (Table S6). In particular, we identified the insertion element IS1 protein InsB (LDA = 2.47573, p = 0.00937) and transposase (LDA = 2.44395, p = 0.00937) as primary ortholog markers reflecting a longer antibody half-life. Further exploration of specific modules and pathways showed that ADP-L-glycero-D-mannohypertose biosynthesis (LDA = 2.50396, p = 0.01614) and photorespiration (LDA = 2.40116, p = 0.04331) were correlated with a longer antibody half-life in PICRUSt analysis, whereas the trehalose biosynthetic pathway (LDA = 2.70821, p = 0.00937) was identified in MinPath analysis.

Association between gut microbiota and acute immune response after BNT162b2 booster vaccination—comparison of the fold changes of anti-S antibody titers

To evaluate acute antibody responses after the BNT162b2 booster vaccination, we divided vaccine recipients into two groups (high versus low responders) based on the median value (34-fold) of the antibody fold-change.

Using 16S rRNA gene sequencing, we did not detect any significant differences in alpha and beta diversity between the two groups (data not shown). Table 2 shows the gut microbiota that potentially contributed to significant fold changes in antibody titers following booster vaccination. In species-level analysis, F. prausnitzii, a member of the family Ruminococcaceae, was abundant in high responders, exhibiting the highest LDA effect size of 4.40539 (p = 0.03998). Peptoniphilus duerdenii (LDA effect size 2.98548, p = 0.03822) of the family Peptoniphilaceae, JRNA_s (LDA effect size 2.30296, p = 0.04727) of the family Mogibacterium_f, PAC001048_s (LDA effect size 2.18111, p = 0.02423) of the family Ruminococcaceae, and Anaerococcus provencensis (LDA effect size 2.16254, p = 0.01913) of the family Peptoniphilaceae were also significantly enriched in high responders. At the genus level (Table S7), Faecalibacterium, belonging to the family Ruminococcaceae of the order Clostridiales in the phylum Firmicutes, was abundant in high responders, exhibiting the highest LDA effect size of 4.40882 (p = 0.03998). Similarly, Clostridium (LDA effect size 3.65726, p = 0.02734) and Agathobaculum (LDA effect size 2.41073, p = 0.03071), both of the order Clostridiales, were associated with a higher antibody fold-change.Table 2 Species-level taxonomic markers associated with high fold increase in antibody titer following BNT162b2 booster vaccination

Taxon name	Taxon rank	Taxonomy	LDA effect size	p-value	
Faecalibacterium prausnitzii	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Faecalibacterium	4.40539	0.03998	
Peptoniphilus duerdenii	Species	Bacteria: Firmicutes: Tissierellia: Tissierellales: Peptoniphilaceae: Peptoniphilus	2.98548	0.03822	
JRNA_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Mogibacterium_f: JRNA_g	2.30296	0.04727	
PAC001048_s	Species	Bacteria: Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: PAC000672_g	2.18111	0.02423	
Anaerococcus provencensis	Species	Bacteria: Firmicutes: Tissierellia: Tissierellales: Peptoniphilaceae: Anaerococcus	2.16254	0.01913	
LDA, linear discriminant analysis. LDA effect size and p-value are expressed as values of V3

Shotgun sequencing-based microbiota analysis yielded consistent results (Fig. 3). In particular, the species F. prausnitzii (high: 2.8%, low: 1.05%) and P. duerdenii (high: 0.55%, low: 0%) and the genus Faecalibacterium (high: 15.7%, low: 11.2%) were more abundant in high than in low responders.Fig. 3 Shotgun sequencing-based compositional differences in gut microbiota between high and low responders after the BNT162b2 booster vaccination. A Species level. B Genus level

Correlation between abundance of specific gut microbiota and antibody half-life or titer fold changes

To elucidate the correlations between species-level taxonomic markers (with an LDA effect size > 2.0) and antibody half-life in the BNT162b2 and ChAdOx1 vaccine cohorts, we conducted Spearman’s correlation analysis. Significance was determined using criteria of absolute correlation coefficients > 0.4 and p-values < 0.05 (Figure S1). In the BNT162b2 cohort, we observed notable positive correlations between the antibody half-life and F. prausnitzii, Prevotella_uc, PAC001304_s, A. rectalis, PAC001173_s, JPJG_s, PAC001187_s, and PAC001335_s. In contrast, in the ChAdOx1 cohort the antibody half-life was only positively correlated with E. coli. Additionally, F. prausnitzii and JRNA_s were positively correlated with the fold changes in antibody titers.

Shotgun sequencing-based functional gene analysis—comparison of the fold changes of anti-S antibody titers following BNT162b2 booster vaccination

A detailed shotgun-based analysis of BNT162b2 booster vaccine recipients revealed specific functional markers in the gut microbiome (Table 3). In particular, the translation initiation factor IF-1 (LDA = 2.5893, p = 0.0433), ATP-dependent Clp protease, protease subunit (LDA = 2.5134, p = 0.0341), large subunit ribosomal protein L35 (LDA = 2.4083, p = 0.2066), ribosome-binding factor A (LDA = 2.3489, p = 0.0341), bacterial/archaeal transporter family-2 protein (LDA = 2.21821, p = 0.0341), beta-lactamase class A TEM [EC:3.5.2.6] (LDA = 2.2132, p = 0.0178), and excinuclease ABC subunit B (LDA = 2.187, p = 0.03433) were more abundant in high than in low responders. Except for one marker (bacterial/archaeal transporter family-2 protein), high responders showed higher abundances of these primary ortholog markers. Using the Clusters of Orthologous Genes (COG) database, we identified the IstB domain ATP-binding protein (LDA = 2.6756, p = 0.0421) as an important marker of an increased antibody response. This gene is associated with DNA replication, membrane fusion, and gene expression regulation [46]. Furthermore, EC:2.1.1.37 (cytosine-specific DNA methyltransferase) and EC:4.2.3.4 (3-dehydroquinate synthase) were enriched in high responders compared with those in low responders.Table 3 Functional markers associated with high fold increase in antibody titer following BNT162b2 booster vaccination

	Meta shotgun	
Definition	High V4	Low V4	LDA effect size	p-value	
COG (eggNoG)	
 COG1484	IstB domain protein ATP-binding protein	0.116	0.0421	2.6756	0.0421	
Ortholog	
 K02518	Translation initiation factor IF-1	0.2564	0.1872	2.5893	0.0433	
 K01358	ATP-dependent Clp protease, protease subunit [EC:3.4.21.92]	0.168	0.1052	2.5134	0.0341	
 K02916	Large subunit ribosomal protein L35	0.2111	0.1582	2.4083	0.0266	
 K02834	Ribosome-binding factor A	0.133	0.0893	2.3489	0.0341	
 K09936	Bacterial/archaeal transporter family-2 protein	0.0161	0.0415	2.2182	0.0341	
 K18698	Beta-lactamase class A TEM [EC:3.5.2.6]	0.0412	0	2.2132	0.0178	
 K03702	Excinuclease ABC subunit B	0.1087	0.0772	2.187	0.0433	
EC (enzyme commission)	
 2.1.1.37	DNA (cytosine-5-)-methyltransferase	0.1886	0.1208	2.4818	0.1208	
 4.2.3.4	3-dehydroquinate synthase	0.1684	0.1199	2.3975	0.1199	

Discussion

In this longitudinal cohort study of SARS-CoV-2 vaccine recipients, the longevity of anti-S antibodies was significantly associated with the gut microbiota composition. Specifically, F. prausnitzii, Prevotella_uc, and PAC001304_s from the genera Prevotella, as well as G. formicilis, B. dorei, and A. rectalis were associated with a significantly prolonged antibody half-life after SARS-CoV-2 mRNA vaccination. Analysis of the associations between gut microbiota species and fold changes in antibody titers after BNT162b2 booster vaccination revealed that, in comparison to low responders, high responders had a significantly higher abundance of F. prausnitzii, which activates the metabolic pathways EC:2.1.1.37 (cytosine-specific DNA methyltransferase) and EC:4.2.3.4 (3-dehydroquinate synthase).

Antibody longevity is influenced by long-lived plasma cells, which are mainly located in the bone marrow, while the magnitude of the acute antibody response to booster vaccinations is likely determined by memory B-cells. Both long-lived plasma and memory B-cells are influenced by the interaction of B-cells, follicular helper T (Tfh) cells, and follicular dendritic cells in the germinal center of B-cell follicles. Kim et al. discovered that short-chain fatty acids (SCFAs) facilitate Tfh cell differentiation both in vitro and in vivo by upregulating cellular metabolism in activated T-cells [47]. Moreover, SCFAs, notably butyrate, have been shown to increase the population of Foxp3 + regulatory T-cells (Tregs) in the colon [48, 49]. Interestingly, under specific conditions, certain Tregs can be converted into Tfh cells within Peyer’s patches [50, 51].

SCFAs promote antibody production via various mechanisms that profoundly affect the human immune system. First, SCFAs effectively enhance the cellular metabolism of B-cells, providing the necessary energy and building blocks for the activation, differentiation, and antibody production of B-cells. In addition, SCFAs increase mitochondrial energy production and glycolysis, which are essential for plasma cell differentiation [52]. Second, SCFAs are involved in the regulation of cellular metabolic pathways as they are converted to acetyl-CoA, which is used for energy production and fatty acid synthesis. In SCFA-treated B-cells, the levels of acetyl-CoA and lipid droplets increase, thereby fostering B-cell differentiation and antibody production [47]. Third, SCFAs regulate the expression of key genes involved in B-cell differentiation. In particular, they upregulate the expression of the immunoglobulin gene family members and that of genes such as Xbp1, Irf4, and Aicda, which are vital for plasma B-cell differentiation and Ig class switch recombination [47]. Finally, SCFAs activate T-cells and phagocytes, enhancing antibody responses [49, 53–55]. Specifically, SCFAs promote the generation and function of Tfh cells, which play a key role in B-cell differentiation and the germinal center reaction, leading to the production of high-affinity antibodies and long-term humoral responses [47]. In this study, the group with a longer antibody half-life (slow decay) within the BNT162b2 cohort was significantly enriched in F. prausnitzii, which is one of the most important butyrate-producing species [56]. Other SCFA-producing bacterial agents, including members of the genera Prevotella and Bacteroides, as well as the families Ruminococcaceae and Lachnospiraceae, were also significantly abundant in the slow decay group.

Moreover, F. prausnitzii is one of the most abundant bacteria present in the healthy human gut [57], where it plays a crucial role in the induction of colonic Treg cells [58]. Tregs modulate the immune response and maintain immune homeostasis [59]. Therefore, in individuals with a high abundance of F. prausnitzii, the unnecessary nonspecific activation of T-cells might be suppressed, and chronic low-grade inflammation might be reduced, ensuring an appropriate immune response upon exposure to antigens. These findings align with the concept of inflammaging (age-related chronic inflammation), underscoring the decline in the numbers of anti-inflammatory bacteria such as F. prausnitzii in older individuals [60].

Our study suggested a potential association between a high abundance of E. coli in the gut and an extended antibody half-life in ChAdOx1 vaccine recipients. Antibody half-life is modulated by several factors, including the magnitude of the immune response, antibody production efficiency, and degradation kinetics. E. coli secretes signaling molecules with notable immunostimulatory properties such as LTA1 (A1 domain of heat-labile enterotoxin), monophosphoryl lipid A, and maltose-binding protein, which are instrumental in dendritic cell (DC) activation [61–63]. Upon activation, DCs relocate to the proximate lymph nodes to present the antigens to T-cells, potentially initiating T- and B-cell activation. Furthermore, E. coli has been suggested to amplify the activity of proinflammatory CD4 + T-cells, potentially heightening the responsiveness to vaccine antigens [64]. In the case of adenovirus-vector vaccines, the quantitative and qualitative activity of DCs may be particularly important in inducing a strong and durable immune response [65].

In the slow-decay group of the BNT162b2 cohort, a notable activation of Kyoto Encyclopedia of Genes and Genomes (KEGG) orthologs K21572 and K21573, which are starch-binding outer membrane proteins, was observed. Specifically, K21572 was associated with the SusD/RagB family, whereas K21573 was associated with SusC. These proteins play pivotal roles in starch binding and transport. A significant proportion of Bacteroidetes strains, particularly those belonging to the genera Prevotella and Bacteroides, have evolved to specialize in the breakdown of complex carbohydrates [66, 67]. The observed increase in the abundance of these microbial species in our taxonomic analysis may be correlated with the heightened activation of the above-mentioned KEGG orthologs. Furthermore, the metabolism of starch and other intricate carbohydrates by gut microbes often leads to SCFA production [68]. Therefore, K21572 and K21573 may influence SCFA synthesis, indirectly affecting antibody longevity.

Memory T-cells, particularly memory Tfh cells, assist in activating B-cells, which then differentiate into antibody-producing plasma cells [69]. Therefore, a strong memory T-cell response can support rapid and robust antibody production during subsequent encounters with a pathogen. In 16S gene analysis of the BNT162b2 cohort, we observed that the ortholog K01897, together with module M00157 and pathway ko00540, which are functional markers of oxidative phosphorylation and lipid metabolism, respectively, were notably activated in the slow antibody decay group. Memory T-cells typically exhibit a metabolic profile that relies more on oxidative phosphorylation and lipid metabolism, whereas activated effector T-cells are more glycolysis-dependent [70]. Given this distinction, our findings suggested that the activation of K01897, M00157, and ko00540 in the slow-decay group may be associated with the activation of memory T-cells.

In shotgun sequencing-based functional gene analysis, we found that the aromatic amino acid synthesis pathways serve as a link between the gut microbiota and the vaccine immune response. The synthesis of aromatic amino acids (L-tyrosine, L-phenylalanine, and L-tryptophan), which are essential for protein biosynthesis in all living organisms, is accomplished via the shikimate and chorismate pathways. These metabolic pathways exist in some protists, bacteria, fungi, and plants, but not in animals [71]. In particular, the shikimate pathway connects primary metabolism and aromatic amino acid biosynthesis. The first enzyme in the shikimate pathway, 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAHPS), generates 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP), while the second enzyme, 3-dehydroquinate synthase (DHQS), converts DAHP into 3-dehydroquinate. DAHPSs are divided into two types according to their amino acid homology: type I DAHPS derived from microorganisms, and type II DAHPS found in plants and some microorganisms [72, 73]. F. prausnitzii activates the shikimate and phenylpropanoid pathways by inducing the activity of 3-dehydroquinate synthase (EC:4.2.3.4), which is involved in the early increase in the expression of DAHPS and phenylalanine ammonia lyase (PAL). In this study, shotgun-based analysis revealed that F. prausnitzii and EC:4.2.3.4 were more abundant in high responders to the BNT162b2 booster vaccination. In plants, the expression of DAHPS1 is strongly induced within 1 h of wound infection, whereas the expression of PAL has been reported to play a major role in inducing resistance to cassava brown streak disease by pathogenic viruses, reflecting early immune responses [74, 75]. In contrast, EC:2.1.1.37 (cytosine-specific DNA methyltransferase), another enriched enzyme in high responders, is known to be involved in gene expression, genome protection against selfish DNA developmental regulation, and T-cell development [76]. Furthermore, six ortholog markers, which were more abundant in high responders, are also involved in maintaining and regulating cellular functions, such as protein synthesis, DNA damage removal, and resynthesis. Considering the results of taxonomic and functional analyses, including enzyme and ortholog analyses (Table 3), the gut microbiome may be significantly associated with the vaccine immune response at the cellular level.

As discussed above so far, the gut microbiota composition might play an important role in modulating the process of immune response after vaccination. Growing evidences have shown that the abundance of phylum Actinobacteria is consistently associated with good vaccine immune responses [77]. Some genera and species of Firmicutes and Proteobacteria is also known to affect vaccine immune responses [77]. Conversely, the composition of gut microbiome is also affected by vaccination as shown among the BNT162b2 recipients in this study. Vaccination might induce changes in the gut microbiota composition, thereby influencing vaccine immunogenicity. A recent study reported that both inactivated and mRNA SARS-CoV-2 vaccination led to lower gut microbial diversity with the relatively high abundance of Bacteroides caccae and low abundance of Coprococcus comes, Dorea longicatena and Ruminococcus obeum [18]. Several studies have highlighted the bidirectional relationship between the gut microbiota and vaccine efficacy, emphasizing that the gut microbiota can influence the immune response to vaccines—including cholera, rotavirus, hepatitis B, tetanus, and influenza vaccines, not limited to the COVID-19 vaccine—and that vaccination itself can also lead to changes in the gut microbiota [78–80]. It is uncertain whether the composition of gut microbiota is influenced mainly by the vaccine platform or by the antigen itself in relation to the immune response pattern.

This study had several strengths, including both short- and long-term assessments of vaccine immunogenicity and its association with the gut microbiome. Moreover, the linkage between the microbiota and functional pathways could be confirmed more clearly by performing both 16S rRNA and shotgun sequencing. However, this study also had some limitations. First, as this was an observational cohort study, establishing causality between specific microbiota/metabolites and vaccine immune responses was not feasible. Second, the participants in this study were healthy individuals; we did not include groups of older individuals or those with chronic medical conditions. Finally, the sample size was limited due to the rapidly evolving pandemic situation. It was necessary to exclude individuals who had contracted COVID-19 and to enroll participants who received the COVID-19 vaccine within a short timeframe that aligned with the study schedule. These limitations should be addressed in future studies to enable the investigation of causality in a more diverse cohort of participants.

In conclusion, the longevity of COVID-19 vaccine immunity was significantly associated with the composition of the gut microbiota. We showed for the first time the beneficial impact of F. prausnitzii in short and long-term vaccine immune responses and identified several intermediate metabolites and enzymes as potential postbiotic candidates for vaccine microbiome adjuvants. The results of this study provide evidence for a gut microbiome-based personalized approach for enhancing vaccine efficacy.

Supplementary Information

Additional file 1.

Abbreviations

ACE Abundance-based coverage estimator

COG Clusters of Orthologous Genes

HUMAnN HMP Unified Metabolic Analysis Network

KEGG Kyoto Encyclopedia of Genes and Genomes

LDA Linear discriminant analysis

MTP Microbiome Taxonomic Profiling

NRF National Research Foundation

OTU Operational taxonomic units

PAL Phenylalanine ammonia lyase

PCoA Principal coordinate analysis

SCFA Short-chain fatty acids

Acknowledgements

We express our gratitude and appreciation to Hanul Choi for her dedicated support during this research. We also thank Seolhee Lee, Heekyung Lee, and Yeseul Yoo for their assistance.

Author contributions

HS, JGY, JYN, HJC, WJK, and JYS conceptualized the study. HS, SL and JYS acquired the funding. HS, JGY, and SL collected the samples and metadata. SL processed the samples. HS, SL, and YH did the data analysis. HS and SL created the figures. HS, SL and JYS wrote the original draft of the manuscript. EN, YJC, EHK, CK, and JYS edited the manuscript. HS, SL, and JYS accessed and verified all the data reported in this study. All authors had full access to all the data in the study and agreed to the final decision to submit for publication. Cocorrespondence is necessary because both authors participated in hypotheses development and design of the study, and each made special contributions in clinical and analytical aspects.

Funding

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF), which is funded by the Korean government MSIT grants NRF-2021M3E5D1A01015187 (to H.S.); the Basic Science Research Program through the NRF funded by the Ministry of Education NRF-2021R1I1A1A01050391 (to H.S.) and RS-2023-00249465 (to S.L.); and a grant from the SK Bioscience Co. Ltd. Q2208691 (to J.Y.S.).

Availability of data and materials

The study data are not publicly available owing to ethical and regulatory restrictions on participant privacy. However, a pseudonymized individual study dataset will be made available from the corresponding author upon request.

Declarations

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Walsh EE Frenck RW Jr Falsey AR Kitchin N Absalon J Gurtman A Lockhart S Neuzil K Mulligan MJ Bailey R Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates N Engl J Med 2020 383 2439 2450 10.1056/NEJMoa2027906 33053279
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383:2439–50.33053279 10.1056/NEJMoa2027906
2. Song JY Choi WS Heo JY Kim EJ Lee JS Jung DS Kim SW Park KH Eom JS Jeong SJ Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial EClinicalMedicine 2023 64 102140 10.1016/j.eclinm.2023.102140 37711219
Song JY, Choi WS, Heo JY, Kim EJ, Lee JS, Jung DS, Kim SW, Park KH, Eom JS, Jeong SJ, et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial. EClinicalMedicine. 2023;64: 102140.37711219 10.1016/j.eclinm.2023.102140
3. Wu Z Hu Y Xu M Chen Z Yang W Jiang Z Li M Jin H Cui G Chen P Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Lancet Infect Dis 2021 21 803 812 10.1016/S1473-3099(20)30987-7 33548194
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:803–12.33548194 10.1016/S1473-3099(20)30987-7
4. Ramasamy MN Minassian AM Ewer KJ Flaxman AL Folegatti PM Owens DR Voysey M Aley PK Angus B Babbage G Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Lancet 2021 396 1979 1993 10.1016/S0140-6736(20)32466-1 33220855
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–93.33220855 10.1016/S0140-6736(20)32466-1
5. Ward H Whitaker M Flower B Tang SN Atchison C Darzi A Donnelly CA Cann A Diggle PJ Ashby D Population antibody responses following COVID-19 vaccination in 212,102 individuals Nat Commun 2022 13 907 10.1038/s41467-022-28527-x 35173150
Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, Donnelly CA, Cann A, Diggle PJ, Ashby D, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13:907.35173150 10.1038/s41467-022-28527-x
6. Yoshida T Mei H Dörner T Hiepe F Radbruch A Fillatreau S Hoyer BF Memory B and memory plasma cells Immunol Rev 2010 237 117 139 10.1111/j.1600-065X.2010.00938.x 20727033
Yoshida T, Mei H, Dörner T, Hiepe F, Radbruch A, Fillatreau S, Hoyer BF. Memory B and memory plasma cells. Immunol Rev. 2010;237:117–39.20727033 10.1111/j.1600-065X.2010.00938.x
7. Manz RA Thiel A Radbruch A Lifetime of plasma cells in the bone marrow Nature 1997 388 133 134 10.1038/40540 9217150
Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388:133–4.9217150 10.1038/40540
8. Nguyen DC Joyner CJ Sanz I Lee FE Factors affecting early antibody secreting cell maturation into long-lived plasma cells Front Immunol 2019 10 2138 10.3389/fimmu.2019.02138 31572364
Nguyen DC, Joyner CJ, Sanz I, Lee FE. Factors affecting early antibody secreting cell maturation into long-lived plasma cells. Front Immunol. 2019;10:2138.31572364 10.3389/fimmu.2019.02138
9. Goel RR Painter MM Apostolidis SA Mathew D Meng W Rosenfeld AM Lundgreen KA Reynaldi A Khoury DS Pattekar A mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern Science 1979 2021 374 abm0829
Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 1979;2021(374):abm0829.
10. Terreri S Piano Mortari E Vinci MR Russo C Alteri C Albano C Colavita F Gramigna G Agrati C Linardos G Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections Cell Host Microbe 2022 30 400 408.e404 10.1016/j.chom.2022.01.003 35134333
Terreri S, Piano Mortari E, Vinci MR, Russo C, Alteri C, Albano C, Colavita F, Gramigna G, Agrati C, Linardos G, et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host Microbe. 2022;30:400-408.e404.35134333 10.1016/j.chom.2022.01.003
11. Praharaj I John SM Bandyopadhyay R Kang G Probiotics, antibiotics and the immune responses to vaccines Philos Trans R Soc Lond B Biol Sci 2015 370 20140144 10.1098/rstb.2014.0144 25964456
Praharaj I, John SM, Bandyopadhyay R, Kang G. Probiotics, antibiotics and the immune responses to vaccines. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140144.25964456 10.1098/rstb.2014.0144
12. Lynn DJ Benson SC Lynn MA Pulendran B Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms Nat Rev Immunol 2021 10.1038/s41577-021-00554-7 34002068
Lynn DJ, Benson SC, Lynn MA, Pulendran B. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat Rev Immunol. 2021. 10.1038/s41577-021-00554-7.34002068 10.1038/s41577-021-00554-7
13. Hanada S Pirzadeh M Carver KY Deng JC Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia Front Immunol 2018 9 2640 10.3389/fimmu.2018.02640 30505304
Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol. 2018;9:2640.30505304 10.3389/fimmu.2018.02640
14. Zheng D Liwinski T Elinav E Interaction between microbiota and immunity in health and disease Cell Res 2020 30 492 506 10.1038/s41422-020-0332-7 32433595
Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492–506.32433595 10.1038/s41422-020-0332-7
15. Li Y Ye Z Zhu J Fang S Meng L Zhou C Effects of gut microbiota on host adaptive immunity under immune homeostasis and tumor pathology state Front Immunol 2022 13 844335 10.3389/fimmu.2022.844335 35355998
Li Y, Ye Z, Zhu J, Fang S, Meng L, Zhou C. Effects of gut microbiota on host adaptive immunity under immune homeostasis and tumor pathology state. Front Immunol. 2022;13:844335.35355998 10.3389/fimmu.2022.844335
16. Yoo JY Groer M Dutra SVO Sarkar A McSkimming DI Gut microbiota and immune system interactions Microorganisms 2020 8 1587 10.3390/microorganisms8101587 33076307
Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut microbiota and immune system interactions. Microorganisms. 2020;8:1587.33076307 10.3390/microorganisms8101587
17. Belkaid Y Hand TW Role of the microbiota in immunity and inflammation Cell 2014 157 121 141 10.1016/j.cell.2014.03.011 24679531
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–41.24679531 10.1016/j.cell.2014.03.011
18. Ng SC Peng Y Zhang L Mok CK Zhao S Li A Ching JY Liu Y Yan S Chan DLS Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events Gut 2022 71 1106 1116 10.1136/gutjnl-2021-326563 35140064
Ng SC, Peng Y, Zhang L, Mok CK, Zhao S, Li A, Ching JY, Liu Y, Yan S, Chan DLS, et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut. 2022;71:1106–16.35140064 10.1136/gutjnl-2021-326563
19. Seong H Choi BK Han YH Kim JH Gim JA Lim S Noh JY Cheong HJ Kim WJ Song JY Gut microbiota as a potential key to modulating humoral immunogenicity of new platform COVID-19 vaccines Signal Transduct Target Ther 2023 8 178 10.1038/s41392-023-01445-0 37137906
Seong H, Choi BK, Han YH, Kim JH, Gim JA, Lim S, Noh JY, Cheong HJ, Kim WJ, Song JY. Gut microbiota as a potential key to modulating humoral immunogenicity of new platform COVID-19 vaccines. Signal Transduct Target Ther. 2023;8:178.37137906 10.1038/s41392-023-01445-0
20. Alexander JL Mullish BH Danckert NP Liu Z Olbei ML Saifuddin A Torkizadeh M Ibraheim H Blanco JM Roberts LA The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients EBioMedicine 2023 88 104430 10.1016/j.ebiom.2022.104430 36634565
Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, et al. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. EBioMedicine. 2023;88: 104430.36634565 10.1016/j.ebiom.2022.104430
21. Chao A Lee S-M Estimating the number of classes via sample coverage J Am Stat Assoc 1992 87 210 217 10.1080/01621459.1992.10475194
Chao A, Lee S-M. Estimating the number of classes via sample coverage. J Am Stat Assoc. 1992;87:210–7.10.1080/01621459.1992.10475194
22. Chao A Estimating the population size for capture-recapture data with unequal catchability Biometrics 1987 43 783 791 10.2307/2531532 3427163
Chao A. Estimating the population size for capture-recapture data with unequal catchability. Biometrics. 1987;43:783–91.3427163 10.2307/2531532
23. Burnham KP Overton WS Robust estimation of population size when capture probabilities vary among animals Ecology 1979 60 927 936 10.2307/1936861
Burnham KP, Overton WS. Robust estimation of population size when capture probabilities vary among animals. Ecology. 1979;60:927–36.10.2307/1936861
24. Magurran AE Measuring biological diversity 2013 Hoboken Wiley
Magurran AE. Measuring biological diversity. Hoboken: Wiley; 2013.
25. Chao A Shen T-J Nonparametric estimation of Shannon’s index of diversity when there are unseen species in sample Environ Ecol Stat 2003 10 429 443 10.1023/A:1026096204727
Chao A, Shen T-J. Nonparametric estimation of Shannon’s index of diversity when there are unseen species in sample. Environ Ecol Stat. 2003;10:429–43.10.1023/A:1026096204727
26. Faith DP Conservation evaluation and phylogenetic diversity Biol Cons 1992 61 1 10 10.1016/0006-3207(92)91201-3
Faith DP. Conservation evaluation and phylogenetic diversity. Biol Cons. 1992;61:1–10.10.1016/0006-3207(92)91201-3
27. Lin J Divergence measures based on the Shannon entropy IEEE Trans Inf Theory 1991 37 145 151 10.1109/18.61115
Lin J. Divergence measures based on the Shannon entropy. IEEE Trans Inf Theory. 1991;37:145–51.10.1109/18.61115
28. Beals EW Bray-Curtis ordination: an effective strategy for analysis of multivariate ecological data Adv Ecol Res 1984 14 1 55 10.1016/S0065-2504(08)60168-3
Beals EW. Bray-Curtis ordination: an effective strategy for analysis of multivariate ecological data. Adv Ecol Res. 1984;14:1–55.10.1016/S0065-2504(08)60168-3
29. Chen J Bittinger K Charlson ES Hoffmann C Lewis J Wu GD Collman RG Bushman FD Li H Associating microbiome composition with environmental covariates using generalized UniFrac distances Bioinformatics 2012 28 2106 2113 10.1093/bioinformatics/bts342 22711789
Chen J, Bittinger K, Charlson ES, Hoffmann C, Lewis J, Wu GD, Collman RG, Bushman FD, Li H. Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics. 2012;28:2106–13.22711789 10.1093/bioinformatics/bts342
30. Hamady M Lozupone C Knight R Fast UniFrac: facilitating high-throughput phylogenetic analyses of microbial communities including analysis of pyrosequencing and PhyloChip data ISME J 2010 4 17 27 10.1038/ismej.2009.97 19710709
Hamady M, Lozupone C, Knight R. Fast UniFrac: facilitating high-throughput phylogenetic analyses of microbial communities including analysis of pyrosequencing and PhyloChip data. ISME J. 2010;4:17–27.19710709 10.1038/ismej.2009.97
31. Segata N Izard J Waldron L Gevers D Miropolsky L Garrett WS Huttenhower C Metagenomic biomarker discovery and explanation Genome Biol 2011 12 1 18 10.1186/gb-2011-12-6-r60
Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:1–18.10.1186/gb-2011-12-6-r60
32. Ye Y Doak TG A parsimony approach to biological pathway reconstruction/inference for genomes and metagenomes PLoS Comput Biol 2009 5 e1000465 10.1371/journal.pcbi.1000465 19680427
Ye Y, Doak TG. A parsimony approach to biological pathway reconstruction/inference for genomes and metagenomes. PLoS Comput Biol. 2009;5: e1000465.19680427 10.1371/journal.pcbi.1000465
33. Langille MG Zaneveld J Caporaso JG McDonald D Knights D Reyes JA Clemente JC Burkepile DE Thurber RLV Knight R Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences Nat Biotechnol 2013 31 814 821 10.1038/nbt.2676 23975157
Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Thurber RLV, Knight R. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814–21.23975157 10.1038/nbt.2676
34. Myers EW Miller W Optimal alignments in linear space Comput Appl Biosci 1988 4 11 17 3382986
Myers EW, Miller W. Optimal alignments in linear space. Comput Appl Biosci. 1988;4:11–7.3382986
35. Wheeler TJ Eddy SR nhmmer: DNA homology search with profile HMMs Bioinformatics 2013 29 2487 2489 10.1093/bioinformatics/btt403 23842809
Wheeler TJ, Eddy SR. nhmmer: DNA homology search with profile HMMs. Bioinformatics. 2013;29:2487–9.23842809 10.1093/bioinformatics/btt403
36. Rognes T Flouri T Nichols B Quince C Mahé F VSEARCH: a versatile open source tool for metagenomics PeerJ 2016 4 e2584 10.7717/peerj.2584 27781170
Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4: e2584.27781170 10.7717/peerj.2584
37. Yoon SH Ha SM Kwon S Lim J Kim Y Seo H Chun J Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies Int J Syst Evol Microbiol 2017 67 1613 1617 10.1099/ijsem.0.001755 28005526
Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, Chun J. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int J Syst Evol Microbiol. 2017;67:1613–7.28005526 10.1099/ijsem.0.001755
38. Edgar RC Haas BJ Clemente JC Quince C Knight R UCHIME improves sensitivity and speed of chimera detection Bioinformatics 2011 27 2194 2200 10.1093/bioinformatics/btr381 21700674
Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011;27:2194–200.21700674 10.1093/bioinformatics/btr381
39. Wood DE Lu J Langmead B Improved metagenomic analysis with Kraken 2 Genome Biol 2019 20 257 10.1186/s13059-019-1891-0 31779668
Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol. 2019;20:257.31779668 10.1186/s13059-019-1891-0
40. Chalita M Ha SM Kim YO Oh HS Yoon SH Chun J Improved metagenomic taxonomic profiling using a curated core gene-based bacterial database reveals unrecognized species in the genus Streptococcus Pathogens 2020 9 204 10.3390/pathogens9030204 32164338
Chalita M, Ha SM, Kim YO, Oh HS, Yoon SH, Chun J. Improved metagenomic taxonomic profiling using a curated core gene-based bacterial database reveals unrecognized species in the genus Streptococcus. Pathogens. 2020;9:204.32164338 10.3390/pathogens9030204
41. Langmead B Salzberg SL Fast gapped-read alignment with bowtie 2 Nat Methods 2012 9 357 359 10.1038/nmeth.1923 22388286
Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nat Methods. 2012;9:357–9.22388286 10.1038/nmeth.1923
42. Li H Handsaker B Wysoker A Fennell T Ruan J Homer N Marth G Abecasis G Durbin R The sequence alignment/map format and SAMtools Bioinformatics 2009 25 2078 2079 10.1093/bioinformatics/btp352 19505943
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.19505943 10.1093/bioinformatics/btp352
43. Quinlan AR Hall IM BEDTools: a flexible suite of utilities for comparing genomic features Bioinformatics 2010 26 841 842 10.1093/bioinformatics/btq033 20110278
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–2.20110278 10.1093/bioinformatics/btq033
44. Anderson MJ A new method for non-parametric multivariate analysis of variance Austral Ecol 2001 26 32 46
Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 2001;26:32–46.
45. Beghini F McIver LJ Blanco-Míguez A Dubois L Asnicar F Maharjan S Mailyan A Manghi P Scholz M Thomas AM Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 eLife 2021 10 e65088 10.7554/eLife.65088 33944776
Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A, Manghi P, Scholz M, Thomas AM, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife. 2021;10:e65088.33944776 10.7554/eLife.65088
46. Arias-Palomo E Berger JM An atypical AAA+ ATPase assembly controls efficient transposition through DNA remodeling and transposase recruitment Cell 2015 162 860 871 10.1016/j.cell.2015.07.037 26276634
Arias-Palomo E, Berger JM. An atypical AAA+ ATPase assembly controls efficient transposition through DNA remodeling and transposase recruitment. Cell. 2015;162:860–71.26276634 10.1016/j.cell.2015.07.037
47. Kim M Qie Y Park J Kim CH Gut microbial metabolites fuel host antibody responses Cell Host Microbe 2016 20 202 214 10.1016/j.chom.2016.07.001 27476413
Kim M, Qie Y, Park J, Kim CH. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe. 2016;20:202–14.27476413 10.1016/j.chom.2016.07.001
48. Furusawa Y Obata Y Fukuda S Endo TA Nakato G Takahashi D Nakanishi Y Uetake C Kato K Kato T Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells Nature 2013 504 446 450 10.1038/nature12721 24226770
Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–50.24226770 10.1038/nature12721
49. Smith PM Howitt MR Panikov N Michaud M Gallini CA Bohlooly YM Glickman JN Garrett WS The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis Science 2013 341 569 573 10.1126/science.1241165 23828891
Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73.23828891 10.1126/science.1241165
50. Xie MM Dent AL Unexpected help: follicular regulatory T cells in the germinal center Front Immunol 2018 9 1536 10.3389/fimmu.2018.01536 30013575
Xie MM, Dent AL. Unexpected help: follicular regulatory T cells in the germinal center. Front Immunol. 2018;9:1536.30013575 10.3389/fimmu.2018.01536
51. Tsuji M Komatsu N Kawamoto S Suzuki K Kanagawa O Honjo T Hori S Fagarasan S Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches Science 1979 2009 323 1488 1492
Tsuji M, Komatsu N, Kawamoto S, Suzuki K, Kanagawa O, Honjo T, Hori S, Fagarasan S. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer’s patches. Science. 1979;2009(323):1488–92.
52. Caro-Maldonado A Wang R Nichols AG Kuraoka M Milasta S Sun LD Gavin AL Abel ED Kelsoe G Green DR Rathmell JC Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells J Immunol 2014 192 3626 3636 10.4049/jimmunol.1302062 24616478
Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, Gavin AL, Abel ED, Kelsoe G, Green DR, Rathmell JC. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol. 2014;192:3626–36.24616478 10.4049/jimmunol.1302062
53. Kim MH Kang SG Park JH Yanagisawa M Kim CH Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice Gastroenterology. 2013 145 396 406.e391-310 10.1053/j.gastro.2013.04.056 23665276
Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013;145:396-406.e391-310.23665276 10.1053/j.gastro.2013.04.056
54. Le Poul E Loison C Struyf S Springael JY Lannoy V Decobecq ME Brezillon S Dupriez V Vassart G Van Damme J Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation J Biol Chem 2003 278 25481 25489 10.1074/jbc.M301403200 12711604
Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003;278:25481–9.12711604 10.1074/jbc.M301403200
55. Park J Kim M Kang SG Jannasch AH Cooper B Patterson J Kim CH Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway Mucosal Immunol 2015 8 80 93 10.1038/mi.2014.44 24917457
Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, Kim CH. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015;8:80–93.24917457 10.1038/mi.2014.44
56. Louis P Flint HJ Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine FEMS Microbiol Lett 2009 294 1 8 10.1111/j.1574-6968.2009.01514.x 19222573
Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009;294:1–8.19222573 10.1111/j.1574-6968.2009.01514.x
57. Portincasa P Bonfrate L Vacca M De Angelis M Farella I Lanza E Khalil M Wang DQ Sperandio M Di Ciaula A Gut microbiota and short chain fatty acids: implications in glucose homeostasis Int J Mol Sci 2022 23 1105 10.3390/ijms23031105 35163038
Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E, Khalil M, Wang DQ, Sperandio M, Di Ciaula A. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23:1105.35163038 10.3390/ijms23031105
58. Alameddine J Godefroy E Papargyris L Sarrabayrouse G Tabiasco J Bridonneau C Yazdanbakhsh K Sokol H Altare F Jotereau F Faecalibacterium prausnitzii skews human DC to prime IL10-producing T cells through TLR2/6/JNK signaling and IL-10, IL-27, CD39, and IDO-1 induction Front Immunol 2019 10 143 10.3389/fimmu.2019.00143 30787928
Alameddine J, Godefroy E, Papargyris L, Sarrabayrouse G, Tabiasco J, Bridonneau C, Yazdanbakhsh K, Sokol H, Altare F, Jotereau F. Faecalibacterium prausnitzii skews human DC to prime IL10-producing T cells through TLR2/6/JNK signaling and IL-10, IL-27, CD39, and IDO-1 induction. Front Immunol. 2019;10:143.30787928 10.3389/fimmu.2019.00143
59. Josefowicz SZ Lu LF Rudensky AY Regulatory T cells: mechanisms of differentiation and function Annu Rev Immunol 2012 30 531 564 10.1146/annurev.immunol.25.022106.141623 22224781
Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64.22224781 10.1146/annurev.immunol.25.022106.141623
60. Miquel S Martín R Rossi O Bermúdez-Humarán LG Chatel JM Sokol H Thomas M Wells JM Langella P Faecalibacterium prausnitzii and human intestinal health Curr Opin Microbiol 2013 16 255 261 10.1016/j.mib.2013.06.003 23831042
Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, Thomas M, Wells JM, Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16:255–61.23831042 10.1016/j.mib.2013.06.003
61. Valli E Baudier RL Harriett AJ Norton EB LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanisms PLoS ONE 2020 15 e0227047 10.1371/journal.pone.0227047 31929548
Valli E, Baudier RL, Harriett AJ, Norton EB. LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanisms. PLoS ONE. 2020;15: e0227047.31929548 10.1371/journal.pone.0227047
62. Jeong Y Kim GB Ji Y Kwak GJ Nam GH Hong Y Kim S An J Kim SH Yang Y Dendritic cell activation by an E coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade Cancer Lett. 2020 472 19 28 10.1016/j.canlet.2019.12.012 31857157
Jeong Y, Kim GB, Ji Y, Kwak GJ, Nam GH, Hong Y, Kim S, An J, Kim SH, Yang Y, et al. Dendritic cell activation by an E coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade. Cancer Lett. 2020;472:19–28.31857157 10.1016/j.canlet.2019.12.012
63. Fernandez S Palmer DR Simmons M Sun P Bisbing J McClain S Mani S Burgess T Gunther V Sun W Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells Infect Immun 2007 75 1359 1363 10.1128/IAI.00486-06 17220311
Fernandez S, Palmer DR, Simmons M, Sun P, Bisbing J, McClain S, Mani S, Burgess T, Gunther V, Sun W. Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells. Infect Immun. 2007;75:1359–63.17220311 10.1128/IAI.00486-06
64. Michaelis L Treß M Löw HC Klees J Klameth C Lange A Grießhammer A Schäfer A Menz S Steimle A Gut Commensal-induced IκBζ expression in dendritic cells influences the Th17 response Front Immunol 2020 11 612336 10.3389/fimmu.2020.612336 33542719
Michaelis L, Treß M, Löw HC, Klees J, Klameth C, Lange A, Grießhammer A, Schäfer A, Menz S, Steimle A, et al. Gut Commensal-induced IκBζ expression in dendritic cells influences the Th17 response. Front Immunol. 2020;11: 612336.33542719 10.3389/fimmu.2020.612336
65. Mercier S Gahéry-Segard H Monteil M Lengagne R Guillet JG Eloit M Denesvre C Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product J Virol 2002 76 2899 2911 10.1128/JVI.76.6.2899-2911.2002 11861857
Mercier S, Gahéry-Segard H, Monteil M, Lengagne R, Guillet JG, Eloit M, Denesvre C. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol. 2002;76:2899–911.11861857 10.1128/JVI.76.6.2899-2911.2002
66. Cheng J Hu J Geng F Nie S Bacteroides utilization for dietary polysaccharides and their beneficial effects on gut health Food Sci Human Wellness 2022 11 1101 1110 10.1016/j.fshw.2022.04.002
Cheng J, Hu J, Geng F, Nie S. Bacteroides utilization for dietary polysaccharides and their beneficial effects on gut health. Food Sci Human Wellness. 2022;11:1101–10.10.1016/j.fshw.2022.04.002
67. Fehlner-Peach H Magnabosco C Raghavan V Scher JU Tett A Cox LM Gottsegen C Watters A Wiltshire-Gordon JD Segata N Distinct polysaccharide utilization profiles of human intestinal prevotella copri isolates Cell Host Microbe 2019 26 680 690.e685 10.1016/j.chom.2019.10.013 31726030
Fehlner-Peach H, Magnabosco C, Raghavan V, Scher JU, Tett A, Cox LM, Gottsegen C, Watters A, Wiltshire-Gordon JD, Segata N, et al. Distinct polysaccharide utilization profiles of human intestinal prevotella copri isolates. Cell Host Microbe. 2019;26:680-690.e685.31726030 10.1016/j.chom.2019.10.013
68. Arpaia N Campbell C Fan X Dikiy S van der Veeken J deRoos P Liu H Cross JR Pfeffer K Coffer PJ Rudensky AY Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation Nature 2013 504 451 455 10.1038/nature12726 24226773
Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–5.24226773 10.1038/nature12726
69. Crotty S T follicular helper cell differentiation, function, and roles in disease Immunity 2014 41 529 542 10.1016/j.immuni.2014.10.004 25367570
Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529–42.25367570 10.1016/j.immuni.2014.10.004
70. Raynor JL Chapman NM Chi H Metabolic control of memory T-cell generation and stemness Cold Spring Harb Perspect Biol 2021 13 a037770 10.1101/cshperspect.a037770 33820774
Raynor JL, Chapman NM, Chi H. Metabolic control of memory T-cell generation and stemness. Cold Spring Harb Perspect Biol. 2021;13: a037770.33820774 10.1101/cshperspect.a037770
71. Galili G Höfgen R Metabolic engineering of amino acids and storage proteins in plants Metab Eng 2002 4 3 11 10.1006/mben.2001.0203 11800569
Galili G, Höfgen R. Metabolic engineering of amino acids and storage proteins in plants. Metab Eng. 2002;4:3–11.11800569 10.1006/mben.2001.0203
72. Benfey PN Chua NH Regulated genes in transgenic plants Science 1979 1989 244 174 181
Benfey PN, Chua NH. Regulated genes in transgenic plants. Science. 1979;1989(244):174–81.
73. Wu J Woodard RW New insights into the evolutionary links relating to the 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase subfamilies J Biol Chem 2006 281 4042 4048 10.1074/jbc.M512223200 16339761
Wu J, Woodard RW. New insights into the evolutionary links relating to the 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase subfamilies. J Biol Chem. 2006;281:4042–8.16339761 10.1074/jbc.M512223200
74. Kavil S Otti G Bouvaine S Armitage A Maruthi MN PAL1 gene of the phenylpropanoid pathway increases resistance to the Cassava brown streak virus in cassava Virol J 2021 18 184 10.1186/s12985-021-01649-2 34503522
Kavil S, Otti G, Bouvaine S, Armitage A, Maruthi MN. PAL1 gene of the phenylpropanoid pathway increases resistance to the Cassava brown streak virus in cassava. Virol J. 2021;18:184.34503522 10.1186/s12985-021-01649-2
75. Görlach J Raesecke HR Rentsch D Regenass M Roy P Zala M Keel C Boller T Amrhein N Schmid J Temporally distinct accumulation of transcripts encoding enzymes of the prechorismate pathway in elicitor-treated, cultured tomato cells Proc Natl Acad Sci USA 1995 92 3166 3170 10.1073/pnas.92.8.3166 11607524
Görlach J, Raesecke HR, Rentsch D, Regenass M, Roy P, Zala M, Keel C, Boller T, Amrhein N, Schmid J. Temporally distinct accumulation of transcripts encoding enzymes of the prechorismate pathway in elicitor-treated, cultured tomato cells. Proc Natl Acad Sci USA. 1995;92:3166–70.11607524 10.1073/pnas.92.8.3166
76. Pradhan S Esteve PO Mammalian DNA (cytosine-5) methyltransferases and their expression Clin Immunol 2003 109 6 16 10.1016/S1521-6616(03)00204-3 14585271
Pradhan S, Esteve PO. Mammalian DNA (cytosine-5) methyltransferases and their expression. Clin Immunol. 2003;109:6–16.14585271 10.1016/S1521-6616(03)00204-3
77. Zimmermann P The immunological interplay between vaccination and the intestinal microbiota Npj Vaccines 2023 8 24 10.1038/s41541-023-00627-9 36823142
Zimmermann P. The immunological interplay between vaccination and the intestinal microbiota. Npj Vaccines. 2023;8:24.36823142 10.1038/s41541-023-00627-9
78. de Jong SE Olin A Pulendran B The impact of the microbiome on immunity to vaccination in humans Cell Host Microbe 2020 28 169 179 10.1016/j.chom.2020.06.014 32791110
de Jong SE, Olin A, Pulendran B. The impact of the microbiome on immunity to vaccination in humans. Cell Host Microbe. 2020;28:169–79.32791110 10.1016/j.chom.2020.06.014
79. Oh JZ Ravindran R Chassaing B Carvalho FA Maddur MS Bower M Hakimpour P Gill KP Nakaya HI Yarovinsky F TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination Immunity 2014 41 478 492 10.1016/j.immuni.2014.08.009 25220212
Oh JZ, Ravindran R, Chassaing B, Carvalho FA, Maddur MS, Bower M, Hakimpour P, Gill KP, Nakaya HI, Yarovinsky F, et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity. 2014;41:478–92.25220212 10.1016/j.immuni.2014.08.009
80. Harris VC Armah G Fuentes S Korpela KE Parashar U Victor JC Tate J de Weerth C Giaquinto C Wiersinga WJ Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana J Infect Dis 2017 215 34 41 10.1093/infdis/jiw518 27803175
Harris VC, Armah G, Fuentes S, Korpela KE, Parashar U, Victor JC, Tate J, de Weerth C, Giaquinto C, Wiersinga WJ, et al. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J Infect Dis. 2017;215:34–41.27803175 10.1093/infdis/jiw518
